- Home
- RNA vs CRNX Comparison
RNA vs CRNX Comparison
Compare RNA & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | CRNX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNA | CRNX |
|---|---|---|
| Price | $71.58 | $45.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | $69.26 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 3.7M | 1.5M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,868,000.00 | $1,535,000.00 |
| Revenue This Year | N/A | $405.68 |
| Revenue Next Year | $108.97 | $1,034.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 106.27 | 47.74 |
| 52 Week Low | $21.51 | $24.10 |
| 52 Week High | $71.78 | $60.34 |
Technical Indicators
Market Signals| Indicator | RNA | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 77.70 | 57.08 |
| Support Level | $70.42 | $44.45 |
| Resistance Level | $71.78 | $46.82 |
| Average True Range (ATR) | 0.45 | 1.94 |
| MACD | -0.77 | 0.19 |
| Stochastic Oscillator | 85.66 | 66.68 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.